AQ
Therapeutic Areas
Kodiak Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Zenkuda (tarcocimab tedromer) | Wet AMD, Diabetic Retinopathy, Retinal Vein Occlusion | Phase 3 |
| KSI-501 | Wet AMD, Diabetic Macular Edema, Retinal Vein Occlusion, Diabetic Retinopathy | Phase 3 |
| KSI-101 | Macular Edema Secondary to Inflammation (MESI) | Phase 3 |
Leadership Team at Kodiak Sciences
VP
Victor Perlroth
Chairman and Chief Executive Officer
JB
John Borgeson
Chief Financial Officer
DS
Dolly S. Chang
Chief Scientific Officer
PV
Pablo Velazquez-Martin
Chief Medical Officer
LD
Laurent Ducry
SVP, Biologics Development and Manufacturing
HL
Hong Liang
SVP, Development
SR
Stephen Raillard
SVP, Chemical Development and Manufacturing